Bayer (ETR:BAYN) announced that it entered into a definitive agreement to transfer some of its small molecule research unit to Nuvisan for an undisclosed amount.
The agreement is slated to lay a foundation for Nuvisan to establish the Berlin-based research unit and support Bayer’s focus on the flexibility and productivity of its research & development operating model, according to a news release.
Get the full story at our sister site, Drug Discovery & Development
